Nandrolone and Trazodone Interaction: Avoid | Peptide Database

Join others researching Halotestin — share findings, ask questions, and learn from real experiences Halotestin (fluoxymesterone) is a synthetic oral anabolic-androgenic steroid derived from testosterone, first introduced in the late 1950s by Upjohn under the brand name Halotestin. It is characterized by an extraordinarily high androgenic rating of approximately 1900 relative to testosterone, paired with an anabolic rating of roughly 1900 as well, though its real-world muscle-building effects are far less pronounced than these numbers suggest. The compound was originally FDA-approved for the treatment of male hypogonadism and advanced breast cancer in women, though it is rarely prescribed today due to the availability of safer alternatives. Fluoxymesterone does not aromatize to estrogen, meaning it produces no estrogenic side effects such as water retention or gynecomastia. In performance contexts, halotestin is used almost exclusively by advanced athletes and competitive bodybuilders in the final weeks before competition or powerlifting meets, where its ability to dramatically increase aggression, neural drive, and strength output without adding water weight makes it uniquely valuable. It is considered one of the harshest oral steroids with respect to hepatotoxicity and is unsuitable for general physique enhancement or beginner use. Fluoxymesterone exerts its effects primarily through exceptionally strong binding to the androgen receptor (AR), driven by its 9-alpha-fluoro and 11-beta-hydroxyl structural modifications that dramatically enhance receptor affinity beyond that of testosterone or DHT. Despite its extreme androgenic potency, it does not convert to estrogen via the aromatase enzyme, and its direct anabolic effect on skeletal muscle tissue is disproportionately low relative to its androgenic rating, likely due to rapid inactivation in muscle tissue. The compound's performance-enhancing effects are largely mediated through the central nervous system, increasing aggression, motivation, and perceived energy through androgen receptor activation in the brain. Fluoxymesterone also stimulates erythropoietin production, increasing red blood cell mass and oxygen-carrying capacity, which was the basis for its historical use in treating certain anemias. It enhances hemoglobin synthesis and may improve muscular endurance through improved oxygen delivery. The 17-alpha-methylation allows oral bioavailability but imposes significant hepatic stress, as the liver must process the intact steroid through first-pass metabolism. Fluoxymesterone suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis, and its extreme androgenic load can rapidly affect mood, lipid profiles, and prostate tissue.

Multiple randomized controlled trials have demonstrated that berberine (500 mg 2-3x daily) reduces fasting blood glucose by 15-25% and HbA1c by 0.5-0.9% in individuals with type 2 diabetes or insulin resistance. A landmark 2008 study in Metabolism showed berberine was comparable to metformin in glycemic control over a 3-month period. Particularly useful for individuals seeking a non-prescription approach to glucose management. Berberine consistently reduces total cholesterol by 15-20%, LDL cholesterol by 20-25%, and triglycerides by 25-35% across clinical trials. Its PCSK9-inhibitory activity provides a unique lipid-lowering mechanism distinct from statins. May be used alone or as adjunctive therapy alongside other lipid-lowering interventions. Improves insulin sensitivity through multiple mechanisms including AMPK activation and insulin receptor upregulation. Reduces HOMA-IR scores in clinical studies. A practical option for individuals with prediabetes or metabolic syndrome who prefer a supplement-based approach before initiating pharmaceutical therapy. Widely used in the biohacking community to counteract the blood glucose elevations associated with MK-677 (ibutamoren) and exogenous growth hormone use. MK-677 can raise fasting glucose by 5-15 mg/dL through GH-mediated insulin resistance, and berberine's AMPK activation helps offset this effect. Often dosed at 500 mg with the evening meal when MK-677 is taken at night. AMPK activity declines with age, contributing to metabolic dysfunction, reduced autophagy, and increased inflammation. Berberine's potent AMPK activation may help counteract age-related metabolic decline. Preclinical studies suggest berberine extends lifespan in several model organisms, though human longevity data is limited to indirect metabolic biomarker improvements. The combination of glucose-lowering, lipid-lowering, and anti-inflammatory effects positions berberine as a compound with potential cardiovascular benefits. Clinical trials have shown improvements in endothelial function and reductions in carotid intima-media thickness. However, long-term cardiovascular outcome trials have not been conducted. Berberine has demonstrated significant effects on gut microbiota composition, increasing populations of Akkermansia muciniphila and other beneficial bacteria associated with improved metabolic health. These microbiome changes may account for a meaningful portion of berberine's systemic metabolic effects, as much of the compound remains in the gut due to its low oral bioavailability.